Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease

BACKGROUND: Crohn’s disease (CD) patients may benefit from biologic optimization. METHODS: We retrospectively assessed adverse events (AEs) and clinical/endoscopic response after ustekinumab re-induction in CD patients. RESULTS: We identified 28 patients, all with prior biologic exposure. Eight week...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Scott David, Kamp, Kendra, Clark-Snustad, Kindra Dawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802251/
https://www.ncbi.nlm.nih.gov/pubmed/36777048
http://dx.doi.org/10.1093/crocol/otac012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802251/
https://www.ncbi.nlm.nih.gov/pubmed/36777048
http://dx.doi.org/10.1093/crocol/otac012

Ejemplares similares